New hope for young transplant patients: fighting a dangerous side effect
NCT ID NCT06128070
Summary
This study tests whether adding the drug ruxolitinib to two standard medications helps prevent graft-versus-host disease (GVHD) in children and young adults receiving bone marrow transplants for blood cancers. GVHD is a serious complication where donor immune cells attack the patient's body. Researchers aim to see if this three-drug combination is safe and more effective at preventing GVHD than the current standard two-drug approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.